Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)Alyssa A Toorop, Zoé L. E. van Kempen, Caspar E.P. van Munster et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 17
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patientsAlyssa A Toorop, Charlotte E. Teunissen, Mark HJ Wessels et al.|Multiple Sclerosis Journal|2024Cited by 3
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M. Y. Gelissen, Zoé L. E. van Kempen, Alyssa A Toorop et al.|Journal of Neurology Neurosurgery & Psychiatry|2025Cited by 1